FDA Panel Won't Back Broader Use of Merck's Cholesterol Meds
Merck can not claim that its cholesterol-lowering drug Vytorin reduces the risk of heart attacks and strokes in patients with coronary heart disease, concluded an FDA advisory panel.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cholesterol | Coronary Heart Disease | Heart | Heart Disease | Merck | Pharmaceuticals | Stroke | Vytorin